Search filters
Filters
Clear All

Phase

  • 59
  • 97
  • 108
  • 89
  • 14
  • 169
  • 697
  • 454
  • 14
  • 32
  • 1
  • 4
  • 648

Found 699 none trials

A listing of none medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 16520: A Phase Ib-II Trial of Tocilizumab and Atezolizumab in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

99 years or below
All genders
Phase 1
This is an investigator-initiated, open label phase Ib study examining 2nd line atezolizumab and tocilizumab in a cohort of recurrent/metastatic non-small cell lung cancer patients who have received prior immune checkpoint inhibitor therapy with or without other forms of therapy (i.e. chemotherapy, radiation). Patients with driver mutations in EGFR, ALK, …
Learn More

UPCC 21520: The LIMIT KRAS Mutant NSCLC Trial: Lysosome Inhibition to Enhance MAPK Inhibition Targeting KRAS Mutant NSCLC: A Phase 2 Open Label Trial of Binimetinib and Hydroxychloroquine in Patients with Advanced KRAS Mutant Non-Small Cell Lung Cancer

99 years or below
All genders
Phase 2
This study will evaluate using hydroxychloroquine (HCQ) along with binimetinib as an effective method for treating cancer. All patients will receive binimetinib at a standard dose approved for other cancers. The dose of HCQ will also be fixed based on ongoing phase I studies. Eligible subjects will have lung cancer …
Learn More

UPCC 07419: A Phase 1b/2a Multicenter Open-Label Dose Escalation Study to Determine the Maximum Tolerated Dose Assess the Safety Tolerability Pharmacokinetics and Efficacy Of Cc-220 Monotherapy and In Combination With Other Treatments In Subjects With Relapsed and Refractory Multiple Myeloma

99 years or below
All genders
Phase 2
The purpose of this study is to test the safety of an experimental drug CC-220, alone and in combination with other treatments. The study is also designed to define the appropriate dose for further testing of the study drug and these experimental combinations.
Learn More

UPCC 03920: A Phase 1/1b Open-label Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination with Systemic Anti-Cancer Therapies in Subjects with Advanced Solid Tumors

99 years or below
All genders
Phase 1
This is a Phase 1 study that will evaluate the effectiveness of TPST-1120. Subjects may receive TPST-1120 alone or in combination with nivolumab. Subjects eligible to participate are those with advanced solid tumors.
Learn More

A prospective randomized active (warfarin) controlled parallel-arm clinical trial to determine if patients with an On-X aortic valve can be maintained safely and effectively on the factor Xa inhibitor apixaban (PROACT-Xa Trial)

99 years or below
All genders
Phase 1
The purpose of this study is to determine if participants with an On-X Prosthetic Heart Valve / On-X aortic valve (a type of mechanical valve) can be maintained safely and effectively on apixaban, an anticoagulant drug different from warfarin.
Learn More

UPCC 07618:A Multicenter Open label Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.

99 years or below
All genders
TBD
Learn More

A Phase 2 Randomized Controlled Dose-titration Open-Label Study Evaluating the Safety and Efficacy of BIV201 in Addition to Standard of Care Compared to Standard of Care to Reduce the Recurrence of Ascites and Complications in Patients with Refractory Ascites Secondary to Decompensated Liver Cirrhosis

99 years or below
All genders
TBD
Learn More

UPCC 11420: A Phase 1/2 Open-Label Clinical Trial of TC-110 T Cells in Adults With Relapsed Or Refractory Non-Hodgkin Lymphoma (NHL) Or Acute Lymphoblastic Leukemia (ALL)

99 years or below
All genders
Phase 1
8.0
Learn More

UPCC 54419: A Phase II Open-label Multicenter Study to Assess the Efficacy and Safety of AFM13 in Patients with Relapsed or Refractory CD30-positive Peripheral T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT)

99 years or below
All genders
This study enrolls subjects with relapsed or refractory CD30-positive Peripheral T-cell Lymphoma (PTCL) or Transformed Mycosis Fungoides (TMF). The purpose of this study is to learn about the effects of a research medicine called AFM13 and to see how well AFM13 is tolerated. This study is divided in three cohorts, …
Learn More
Evaluation of Vascular Health Profile in Predicting Venous Thromboembolism

Evaluation of Vascular Health Profile in Predicting Venous Thromboembolism

1 years - 99 years
All genders
The main goal of this study is to utilize previously validated cytometric markers of to identify cancer patients at high risk of VTE. The primary outcome will be DVT or pulmonary embolism (PE). Patients with pancreatic and brain cancer will be enrolled as these patients are known to have higher …
Learn More
291 - 300 of 699